STOCK TITAN

[8-K] Teladoc Health, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

On 29 Jul 2025, Transcat, Inc. (TRNS) executed a new five-year $150 million secured revolving credit facility with a three-bank syndicate led by M&T Bank, replacing and terminating its prior $80 million line. The facility provides committed revolving loans, swingline loans and letters of credit and matures on 29 Jul 2030, allowing amounts to be re-borrowed subject to availability.

Pricing & fees: Base-rate borrowings carry 0.00%–0.75% margin, and SOFR loans carry 1.00%–1.75% margin—both lower than the superseded facility. Unused commitments are charged a quarterly fee of 0.10%–0.20%. Overdue amounts accrue an additional 300 bp.

Covenants: leverage ratio ≤3.0× EBITDA (with temporary step-up for “Material Permitted Acquisitions”) and fixed-charge coverage ≥1.20×. Customary negative covenants and default triggers apply; all U.S. subsidiaries guarantee the debt.

Use of proceeds: refinancing the old facility, funding acquisitions, working capital and general corporate purposes. The enlarged, lower-cost facility enhances liquidity, extends tenor by five years and adds structural flexibility for strategic growth.

Il 29 luglio 2025, Transcat, Inc. (TRNS) ha stipulato una nuova linea di credito revolving garantita di 150 milioni di dollari della durata di cinque anni con un sindacato di tre banche guidato da M&T Bank, sostituendo e terminando la precedente linea da 80 milioni di dollari. La struttura prevede prestiti revolving impegnati, prestiti swingline e lettere di credito, con scadenza il 29 luglio 2030, consentendo il riutilizzo degli importi, soggetto a disponibilità.

Condizioni economiche e commissioni: i prestiti a tasso base prevedono un margine compreso tra 0,00% e 0,75%, mentre i prestiti indicizzati al SOFR hanno un margine tra 1,00% e 1,75%—entrambi inferiori rispetto alla precedente linea. Le linee non utilizzate sono soggette a una commissione trimestrale tra 0,10% e 0,20%. Gli importi scaduti maturano un interesse aggiuntivo di 300 punti base.

Vincoli: rapporto di leva finanziaria ≤3,0× EBITDA (con un aumento temporaneo per "Acquisizioni Materiali Consentite") e copertura delle spese fisse ≥1,20×. Sono applicati consueti vincoli negativi e clausole di default; tutte le controllate statunitensi garantiscono il debito.

Utilizzo dei proventi: rifinanziamento della vecchia linea, finanziamento di acquisizioni, capitale circolante e scopi societari generali. La struttura ampliata e a costi inferiori migliora la liquidità, estende la durata di cinque anni e aggiunge flessibilità strutturale per la crescita strategica.

El 29 de julio de 2025, Transcat, Inc. (TRNS) firmó una nueva línea de crédito renovable garantizada por 150 millones de dólares a cinco años con un sindicato bancario de tres entidades liderado por M&T Bank, reemplazando y cancelando su línea previa de 80 millones. La facilidad ofrece préstamos renovables comprometidos, préstamos swingline y cartas de crédito, con vencimiento el 29 de julio de 2030, permitiendo el reembolso de montos según disponibilidad.

Precios y comisiones: los préstamos a tasa base llevan un margen de 0,00% a 0,75%, y los préstamos SOFR un margen de 1,00% a 1,75%, ambos inferiores a la facilidad anterior. Los compromisos no usados tienen una comisión trimestral de 0,10% a 0,20%. Los importes vencidos acumulan un interés adicional de 300 puntos básicos.

Convenios: ratio de apalancamiento ≤3,0× EBITDA (con un aumento temporal para "Adquisiciones Materialmente Permitidas") y cobertura de cargos fijos ≥1,20×. Se aplican convenios negativos habituales y desencadenantes de incumplimiento; todas las subsidiarias estadounidenses garantizan la deuda.

Uso de los fondos: refinanciar la línea anterior, financiar adquisiciones, capital de trabajo y propósitos corporativos generales. La facilidad ampliada y de menor costo mejora la liquidez, extiende el plazo cinco años y añade flexibilidad estructural para el crecimiento estratégico.

2025년 7월 29일, Transcat, Inc. (TRNS)는 M&T Bank가 주도하는 3개 은행 연합과 함께 새로운 5년 만기 1억 5천만 달러 담보 회전 신용 한도를 체결하여 기존 8천만 달러 한도를 대체하고 종료했습니다. 이 신용 한도는 약정된 회전 대출, 스윙라인 대출 및 신용장을 제공하며 2030년 7월 29일에 만기되며, 가용 한도 내에서 재차 대출이 가능합니다.

금리 및 수수료: 기준 금리 대출은 0.00%~0.75%의 마진이 적용되며, SOFR 대출은 1.00%~1.75%의 마진이 적용되어 이전 한도보다 낮습니다. 미사용 약정에는 분기별 0.10%~0.20%의 수수료가 부과됩니다. 연체 금액에는 추가로 300bp가 가산됩니다.

약정 조건: 레버리지 비율은 EBITDA 대비 ≤3.0배(“중요 허용 인수”에 대해 일시적 상향 조정 가능), 고정 비용 커버리지 비율은 ≥1.20배입니다. 일반적인 부정적 약정 및 채무불이행 조항이 적용되며, 모든 미국 자회사가 부채를 보증합니다.

자금 용도: 기존 한도 재융자, 인수 자금 조달, 운전자본 및 일반 기업 목적. 확대되고 비용이 낮아진 이 한도는 유동성을 강화하고 만기를 5년 연장하며 전략적 성장을 위한 구조적 유연성을 제공합니다.

Le 29 juillet 2025, Transcat, Inc. (TRNS) a conclu une nouvelle facilité de crédit renouvelable garantie de 150 millions de dollars sur cinq ans avec un syndicat de trois banques dirigé par M&T Bank, remplaçant et mettant fin à sa ligne précédente de 80 millions. La facilité offre des prêts renouvelables engagés, des prêts swingline et des lettres de crédit, arrivant à échéance le 29 juillet 2030, permettant de réemprunter les montants sous réserve de disponibilité.

Tarification & frais : les emprunts au taux de base portent une marge de 0,00 % à 0,75 %, et les prêts SOFR une marge de 1,00 % à 1,75 % — toutes deux inférieures à la facilité précédente. Les engagements non utilisés sont facturés trimestriellement entre 0,10 % et 0,20 %. Les montants en retard accumulent un supplément de 300 points de base.

Engagements : ratio d’endettement ≤3,0× EBITDA (avec une augmentation temporaire pour les « acquisitions importantes autorisées ») et couverture des charges fixes ≥1,20×. Des clauses négatives habituelles et des déclencheurs de défaut s’appliquent ; toutes les filiales américaines garantissent la dette.

Utilisation des fonds : refinancement de l’ancienne facilité, financement des acquisitions, fonds de roulement et objectifs généraux de l’entreprise. Cette facilité élargie et moins coûteuse améliore la liquidité, prolonge la durée de cinq ans et ajoute une flexibilité structurelle pour la croissance stratégique.

Am 29. Juli 2025 hat Transcat, Inc. (TRNS) eine neue fünfjährige gesicherte revolvierende Kreditlinie in Höhe von 150 Millionen US-Dollar mit einem aus drei Banken bestehenden Konsortium unter Führung der M&T Bank abgeschlossen, die die vorherige 80-Millionen-Dollar-Linie ersetzt und beendet. Die Kreditlinie umfasst zugesagte revolvierende Darlehen, Swingline-Kredite und Akkreditive und läuft am 29. Juli 2030 aus, wobei Beträge je nach Verfügbarkeit erneut aufgenommen werden können.

Konditionen & Gebühren: Darlehen zum Basiszinssatz haben eine Marge von 0,00 % bis 0,75 %, SOFR-Darlehen eine Marge von 1,00 % bis 1,75 % – beides niedriger als bei der vorherigen Kreditlinie. Nicht genutzte Kreditlinien werden vierteljährlich mit 0,10 % bis 0,20 % berechnet. Überfällige Beträge unterliegen einem zusätzlichen Zinssatz von 300 Basispunkten.

Klauseln: Verschuldungsgrad ≤3,0× EBITDA (mit vorübergehendem Anstieg für „Material Permitted Acquisitions“) und Fixkosten-Deckungsgrad ≥1,20×. Übliche Negativklauseln und Auslöser für Vertragsverletzungen gelten; alle US-Tochtergesellschaften garantieren die Schulden.

Verwendung der Mittel: Refinanzierung der alten Kreditlinie, Finanzierung von Akquisitionen, Betriebskapital und allgemeine Unternehmenszwecke. Die erweiterte, kostengünstigere Kreditlinie verbessert die Liquidität, verlängert die Laufzeit um fünf Jahre und bietet strukturelle Flexibilität für strategisches Wachstum.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Bigger, cheaper, longer facility improves liquidity while maintaining conservative covenants; modest rise in leverage risk.

The $150 m revolver nearly doubles capacity and extends maturity to 2030, materially improving TRNS’s liquidity profile. Margin reductions of up to 50 bp versus the prior agreement lower potential interest expense. Covenant headroom remains at 3.0× EBITDA, signalling ongoing balance-sheet discipline, yet management gained flexibility to temporarily exceed this post-acquisition—supportive for M&A strategy but introduces some leverage creep. Overall credit quality is stable to slightly improved.

TL;DR: Facility supports inorganic growth optionality; positive for equity holders if deployed accretively.

The enlarged revolver equips TRNS to pursue bolt-on deals without immediate equity dilution. Lower spreads and modest fees protect margins in a rising-rate environment. However, variable-rate debt ties financing cost to SOFR movements, so future interest expense could rise if rates stay elevated. Equity impact is favourable provided acquisition returns exceed weighted cost of capital.

Il 29 luglio 2025, Transcat, Inc. (TRNS) ha stipulato una nuova linea di credito revolving garantita di 150 milioni di dollari della durata di cinque anni con un sindacato di tre banche guidato da M&T Bank, sostituendo e terminando la precedente linea da 80 milioni di dollari. La struttura prevede prestiti revolving impegnati, prestiti swingline e lettere di credito, con scadenza il 29 luglio 2030, consentendo il riutilizzo degli importi, soggetto a disponibilità.

Condizioni economiche e commissioni: i prestiti a tasso base prevedono un margine compreso tra 0,00% e 0,75%, mentre i prestiti indicizzati al SOFR hanno un margine tra 1,00% e 1,75%—entrambi inferiori rispetto alla precedente linea. Le linee non utilizzate sono soggette a una commissione trimestrale tra 0,10% e 0,20%. Gli importi scaduti maturano un interesse aggiuntivo di 300 punti base.

Vincoli: rapporto di leva finanziaria ≤3,0× EBITDA (con un aumento temporaneo per "Acquisizioni Materiali Consentite") e copertura delle spese fisse ≥1,20×. Sono applicati consueti vincoli negativi e clausole di default; tutte le controllate statunitensi garantiscono il debito.

Utilizzo dei proventi: rifinanziamento della vecchia linea, finanziamento di acquisizioni, capitale circolante e scopi societari generali. La struttura ampliata e a costi inferiori migliora la liquidità, estende la durata di cinque anni e aggiunge flessibilità strutturale per la crescita strategica.

El 29 de julio de 2025, Transcat, Inc. (TRNS) firmó una nueva línea de crédito renovable garantizada por 150 millones de dólares a cinco años con un sindicato bancario de tres entidades liderado por M&T Bank, reemplazando y cancelando su línea previa de 80 millones. La facilidad ofrece préstamos renovables comprometidos, préstamos swingline y cartas de crédito, con vencimiento el 29 de julio de 2030, permitiendo el reembolso de montos según disponibilidad.

Precios y comisiones: los préstamos a tasa base llevan un margen de 0,00% a 0,75%, y los préstamos SOFR un margen de 1,00% a 1,75%, ambos inferiores a la facilidad anterior. Los compromisos no usados tienen una comisión trimestral de 0,10% a 0,20%. Los importes vencidos acumulan un interés adicional de 300 puntos básicos.

Convenios: ratio de apalancamiento ≤3,0× EBITDA (con un aumento temporal para "Adquisiciones Materialmente Permitidas") y cobertura de cargos fijos ≥1,20×. Se aplican convenios negativos habituales y desencadenantes de incumplimiento; todas las subsidiarias estadounidenses garantizan la deuda.

Uso de los fondos: refinanciar la línea anterior, financiar adquisiciones, capital de trabajo y propósitos corporativos generales. La facilidad ampliada y de menor costo mejora la liquidez, extiende el plazo cinco años y añade flexibilidad estructural para el crecimiento estratégico.

2025년 7월 29일, Transcat, Inc. (TRNS)는 M&T Bank가 주도하는 3개 은행 연합과 함께 새로운 5년 만기 1억 5천만 달러 담보 회전 신용 한도를 체결하여 기존 8천만 달러 한도를 대체하고 종료했습니다. 이 신용 한도는 약정된 회전 대출, 스윙라인 대출 및 신용장을 제공하며 2030년 7월 29일에 만기되며, 가용 한도 내에서 재차 대출이 가능합니다.

금리 및 수수료: 기준 금리 대출은 0.00%~0.75%의 마진이 적용되며, SOFR 대출은 1.00%~1.75%의 마진이 적용되어 이전 한도보다 낮습니다. 미사용 약정에는 분기별 0.10%~0.20%의 수수료가 부과됩니다. 연체 금액에는 추가로 300bp가 가산됩니다.

약정 조건: 레버리지 비율은 EBITDA 대비 ≤3.0배(“중요 허용 인수”에 대해 일시적 상향 조정 가능), 고정 비용 커버리지 비율은 ≥1.20배입니다. 일반적인 부정적 약정 및 채무불이행 조항이 적용되며, 모든 미국 자회사가 부채를 보증합니다.

자금 용도: 기존 한도 재융자, 인수 자금 조달, 운전자본 및 일반 기업 목적. 확대되고 비용이 낮아진 이 한도는 유동성을 강화하고 만기를 5년 연장하며 전략적 성장을 위한 구조적 유연성을 제공합니다.

Le 29 juillet 2025, Transcat, Inc. (TRNS) a conclu une nouvelle facilité de crédit renouvelable garantie de 150 millions de dollars sur cinq ans avec un syndicat de trois banques dirigé par M&T Bank, remplaçant et mettant fin à sa ligne précédente de 80 millions. La facilité offre des prêts renouvelables engagés, des prêts swingline et des lettres de crédit, arrivant à échéance le 29 juillet 2030, permettant de réemprunter les montants sous réserve de disponibilité.

Tarification & frais : les emprunts au taux de base portent une marge de 0,00 % à 0,75 %, et les prêts SOFR une marge de 1,00 % à 1,75 % — toutes deux inférieures à la facilité précédente. Les engagements non utilisés sont facturés trimestriellement entre 0,10 % et 0,20 %. Les montants en retard accumulent un supplément de 300 points de base.

Engagements : ratio d’endettement ≤3,0× EBITDA (avec une augmentation temporaire pour les « acquisitions importantes autorisées ») et couverture des charges fixes ≥1,20×. Des clauses négatives habituelles et des déclencheurs de défaut s’appliquent ; toutes les filiales américaines garantissent la dette.

Utilisation des fonds : refinancement de l’ancienne facilité, financement des acquisitions, fonds de roulement et objectifs généraux de l’entreprise. Cette facilité élargie et moins coûteuse améliore la liquidité, prolonge la durée de cinq ans et ajoute une flexibilité structurelle pour la croissance stratégique.

Am 29. Juli 2025 hat Transcat, Inc. (TRNS) eine neue fünfjährige gesicherte revolvierende Kreditlinie in Höhe von 150 Millionen US-Dollar mit einem aus drei Banken bestehenden Konsortium unter Führung der M&T Bank abgeschlossen, die die vorherige 80-Millionen-Dollar-Linie ersetzt und beendet. Die Kreditlinie umfasst zugesagte revolvierende Darlehen, Swingline-Kredite und Akkreditive und läuft am 29. Juli 2030 aus, wobei Beträge je nach Verfügbarkeit erneut aufgenommen werden können.

Konditionen & Gebühren: Darlehen zum Basiszinssatz haben eine Marge von 0,00 % bis 0,75 %, SOFR-Darlehen eine Marge von 1,00 % bis 1,75 % – beides niedriger als bei der vorherigen Kreditlinie. Nicht genutzte Kreditlinien werden vierteljährlich mit 0,10 % bis 0,20 % berechnet. Überfällige Beträge unterliegen einem zusätzlichen Zinssatz von 300 Basispunkten.

Klauseln: Verschuldungsgrad ≤3,0× EBITDA (mit vorübergehendem Anstieg für „Material Permitted Acquisitions“) und Fixkosten-Deckungsgrad ≥1,20×. Übliche Negativklauseln und Auslöser für Vertragsverletzungen gelten; alle US-Tochtergesellschaften garantieren die Schulden.

Verwendung der Mittel: Refinanzierung der alten Kreditlinie, Finanzierung von Akquisitionen, Betriebskapital und allgemeine Unternehmenszwecke. Die erweiterte, kostengünstigere Kreditlinie verbessert die Liquidität, verlängert die Laufzeit um fünf Jahre und bietet strukturelle Flexibilität für strategisches Wachstum.

FALSE000147744900014774492025-07-292025-07-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported) July 29, 2025
___________________________________
Teladoc Health, Inc.
(Exact name of registrant as specified in its charter)
___________________________________

Delaware
(State or other jurisdiction of
incorporation)
001-37477
(Commission File Number)
04-3705970
(I.R.S. Employer Identification No.)
155 E 44th Street Floor 17
New York, NY 10017
(Address of principal executive offices and zip code)
(203) 635-2002
(Registrant's telephone number, including area code)
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common stock, par value $0.001 per shareTDOCThe New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company    
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 2.02.    Results of Operations and Financial Condition.

On July 29, 2025, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the second quarter of 2025. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1.

The foregoing information (including the exhibit set forth in Item 9.01 hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01.    Financial Statements and Exhibits.
(d) Exhibits.

Exhibit No.Description
99.1*
Teladoc Health, Inc. press release, dated July 29, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
* Furnished herewith.







SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 29, 2025
Teladoc Health, Inc.
By:
/s/ Adam C. Vandervoort
Name:
Adam C. Vandervoort
Title:
Chief Legal Officer and Secretary



FAQ

How much larger is Transcat's new credit facility compared to the prior one?

The new revolver is $150 million, nearly double the former $80 million facility.

When does the new TRNS credit facility mature?

It matures on July 29, 2030.

What are the interest rate spreads on the new facility?

Base-rate loans carry 0.00%–0.75%; SOFR loans carry 1.00%–1.75%, depending on leverage.

What leverage covenant does Transcat have to maintain?

A maximum leverage ratio of 3.0× EBITDA, with a temporary increase allowed for qualifying acquisitions.

What can Transcat use the new credit facility for?

Permitted uses include refinancing the old line, acquisitions, working capital and general corporate purposes.
Teladoc Health Inc

NYSE:TDOC

TDOC Rankings

TDOC Latest News

TDOC Latest SEC Filings

TDOC Stock Data

1.44B
173.51M
0.81%
75.9%
14.41%
Health Information Services
Services-offices & Clinics of Doctors of Medicine
Link
United States
PURCHASE